ALLR Allarity Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1860657 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,938.3%
Net margin-4,493.7%
FCF margin-3,785.4%
EBITDA margin—
Returns
ROE-322.7%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets108.3%
Debt / equity—
Current ratio0.91x
Interest coverage-6.83x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue20.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5,000 | $0 | $25,000 | $320,000 | $0 | $0 | $0 | — |
| R&D expense | $4.22M | $1.34M | $1.30M | $1.67M | $1.20M | $2.32M | $1.40M | $1.85M |
| SG&A expense | $1.29M | $1.33M | $1.42M | $1.56M | $1.31M | $1.81M | $1.63M | $5.47M |
| Operating income | -$5.51M | -$2.67M | -$2.69M | -$2.92M | -$2.52M | -$4.13M | -$3.04M | -$7.32M |
| Interest expense | $1.01M | $719,000 | $229,000 | $59,000 | $57,000 | $12,000 | $57,000 | $75,000 |
| Pretax income | — | — | — | -$3.37M | -$2.81M | -$2.32M | -$2.73M | -$7.45M |
| Income tax | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.20M | -$3.40M | -$2.75M | -$3.37M | -$2.81M | -$2.32M | -$2.73M | -$7.45M |
| EBITDA | — | — | — | — | — | -$4.12M | -$3.02M | -$7.32M |
| EPS (basic) | -0.39 | -0.21 | -0.17 | — | -0.19 | -0.15 | -0.25 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.09M | $16.98M | $19.81M | $14.69M | $16.89M | $17.80M | $25.20M | $19.53M |
| Current assets | $26.87M | $31.73M | $34.50M | $17.93M | $20.47M | $20.88M | $29.42M | $22.34M |
| PP&E, net | $354,000 | $386,000 | $420,000 | $330,000 | $330,000 | $322,000 | $308,000 | $309,000 |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $27.22M | $32.12M | $34.92M | $18.26M | $20.80M | $21.20M | $29.73M | $22.65M |
| Current liabilities | $29.48M | $28.58M | $28.00M | $8.43M | $8.79M | $9.04M | $11.06M | $10.84M |
| Short-term debt | $21.58M | $20.86M | $20.08M | $0 | — | — | — | — |
| Total liabilities | $29.48M | $28.58M | $28.00M | $8.43M | $8.79M | $9.04M | $11.06M | $10.84M |
| Shareholders' equity | -$2.26M | $3.54M | $6.92M | $9.83M | $12.01M | $12.17M | $18.67M | $11.81M |
| Shares outstanding | 16.15M | 15.91M | 15.82M | 16.08M | 16.11M | 14.62M | 17.02M | 7.30M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.88M | -$2.56M | -$4.49M | -$3.24M | -$3.41M | -$5.48M | -$2.69M | -$3.21M |
| Capital expenditure | $0 | $0 | $64,000 | $8,000 | $0 | $0 | $0 | — |
| Free cash flow | -$2.88M | -$2.56M | -$4.56M | -$3.25M | -$3.41M | -$5.48M | -$2.69M | — |
| Investing cash flow | $0 | $0 | -$64,000 | -$8,000 | $0 | $0 | $0 | — |
| Financing cash flow | $0 | $0 | $19.74M | -$240,000 | $2.31M | -$2.56M | $11.14M | $4.24M |
| Depreciation & amortization | — | — | — | — | — | $12,000 | $11,000 | $1,000 |
| Stock-based compensation | $191,000 | $188,000 | $160,000 | $47,000 | $132,000 | $164,000 | $139,000 | $64,000 |
| Share buybacks | $0 | $0 | $262,000 | $484,000 | $141,000 | $2.56M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.